PHARMACOECONOMIC EVALUATION OF VANCOMYCIN AND TEICOPLANIN

Abstract

Teicoplanin and vancomycin are antibiotics widely prescribed for the treatment of Gram-positive bacterial infections. This review presents a pharmacoeconomic evaluation comparing the efficacy and cost-effectiveness of these two antibiotics. Clinical studies indicate that teicoplanin demonstrates superior efficacy in treating a range of Gram-positive infections, with higher cure rates and fewer adverse effects compared to vancomycin. Additionally, teicoplanin's pharmacokinetic properties allow for less frequent dosing, enhancing patient compliance and reducing hospital resource utilization. Economically, teicoplanin proves to be more cost-effective due to its lower overall treatment costs, including reduced hospitalization and monitoring expenses. These findings suggest that teicoplanin offers a more effective and economically advantageous option over vancomycin for the management of Gram-positive infections. This review underscores the importance of considering both clinical outcomes and economic factors in antibiotic selection to optimize healthcare resources and patient care.